These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35681795)

  • 1. Mutations in
    Liu D; Benzaquen J; Morris LGT; Ilié M; Hofman P
    Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.
    Zhu G; Ren D; Lei X; Shi R; Zhu S; Zhou N; Zu L; Mello RA; Chen J; Xu S
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
    Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
    Pan D; Hu AY; Antonia SJ; Li CY
    J Thorac Oncol; 2021 Mar; 16(3):419-427. PubMed ID: 33307194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Huang Q; Cao H; Yao Q; Zhou X; Li H; Bai Q; Hu H
    Immunotargets Ther; 2023; 12():165-173. PubMed ID: 38075489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
    Jiang Z; Zhou Y; Huang J
    Front Immunol; 2021; 12():813331. PubMed ID: 35003141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
    McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
    Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
    Zheng M
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
    Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
    J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.
    Liu R; Niu Y; Liu C; Zhang X; Zhang J; Shi M; Zou W; Gu B; Zhu H; Wang D; Yuan H; Li W; Zhao D; Zheng Q; Liu R; Chen W; Ma T; Zhang Y
    Cancer Sci; 2023 Apr; 114(4):1229-1239. PubMed ID: 36601880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging big data of immune checkpoint blockade response identifies novel potential targets.
    Bareche Y; Kelly D; Abbas-Aghababazadeh F; Nakano M; Esfahani PN; Tkachuk D; Mohammad H; Samstein R; Lee CH; Morris LGT; Bedard PL; Haibe-Kains B; Stagg J
    Ann Oncol; 2022 Dec; 33(12):1304-1317. PubMed ID: 36055464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Kim H; Kwon HJ; Kim ES; Kwon S; Suh KJ; Kim SH; Kim YJ; Lee JS; Chung JH
    Cancer Res Treat; 2022 Apr; 54(2):424-433. PubMed ID: 34237208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.
    Yang RK; Qing Y; Jelloul FZ; Routbort MJ; Wang P; Shaw K; Zhang J; Lee J; Medeiros LJ; Kopetz S; Tetzlaff MT; Broaddus RR
    Oncotarget; 2020 Feb; 11(6):600-618. PubMed ID: 32110280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
    Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM
    Front Oncol; 2020; 10():314. PubMed ID: 32232003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.